Boston Scientific, the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Michael Matson from Needham reiterated a Buy rating on the stock and has a $121.00 price target.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Michael Matson has given his Buy rating due to a combination of factors including Boston Scientific’s strong financial performance in the third quarter of 2025. The company exceeded expectations in both revenue and earnings per share, leading to an upward revision of their 2025 financial guidance.
Additionally, the impressive growth of the WATCHMAN device, which saw a significant increase in sales, contributed to the positive outlook. Despite facing challenges such as tariff impacts, Boston Scientific managed to improve its gross and operating margins, showcasing effective cost management. These elements collectively reinforce the company’s robust growth trajectory, justifying the Buy rating.
According to TipRanks, Matson is an analyst with an average return of -2.3% and a 41.48% success rate. Matson covers the Healthcare sector, focusing on stocks such as Boston Scientific, TransMedics Group, and Hologic.
In another report released today, Evercore ISI also maintained a Buy rating on the stock with a $113.00 price target.